التفاصيل البيبلوغرافية
العنوان:
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
المؤلفون:
Steven Lemery , Patricia Keegan , Richard Pazdur
المصدر:
The New England journal of medicine . 377(15)
سنة النشر:
2017
مصطلحات موضوعية:
0301 basic medicine , Oncology , Adult , Male , medicine.medical_specialty , Programmed Cell Death 1 Receptor , Antineoplastic Agents , Breast Neoplasms , Pembrolizumab , Antibodies, Monoclonal, Humanized , Digestive System Neoplasms , B7-H1 Antigen , 03 medical and health sciences , 0302 clinical medicine , Neoplastic Syndromes, Hereditary , Internal medicine , medicine , Drug approval , Biomarkers, Tumor , Humans , Neoplasm Metastasis , Child , Drug Approval , business.industry , Brain Neoplasms , United States Food and Drug Administration , Fda approval , Cancer , General Medicine , medicine.disease , Tumor site , United States , Surgery , 030104 developmental biology , 030220 oncology & carcinogenesis , Monoclonal , Biomarker (medicine) , Female , Microsatellite Instability , Programmed death 1 , business , Colorectal Neoplasms , Urogenital Neoplasms
الوصف:
In May 2017, the FDA approved pembrolizumab, a programmed death 1 inhibitor, for adult and pediatric patients with unresectable or metastatic, microsatellite-instability–high or mismatch-repair–deficient solid tumors, regardless of tumor site or histology.
تدمد:
1533-4406
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68427c62967763e5fc6960ce76a05dbcTest https://pubmed.ncbi.nlm.nih.gov/29020592Test
رقم الانضمام:
edsair.doi.dedup.....68427c62967763e5fc6960ce76a05dbc
قاعدة البيانات:
OpenAIRE
